Device Trial Radar · NCT06928337
Data Collection Protocol for the Development of CHLOE-OQ, an AI Model for Assessing Oocytes Quality.
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
May 1, 2025
Primary completion
May 1, 2026
Study completion May 1, 2026
Sponsor
- Lead sponsor
- FairtilityNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 15, 2025
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This data collection protocol is aimed to allow the reliable and robust development (training, verification, and validations) of CHLOE technology-based applications as well as improve the machine learning stage of released devices/applications. Additionally, a simulated use assessments will be conducted to ensure the correct and easy use of the CHLOE applications.
Conditions
- Fertility Disorders
Interventions
AI evaluation of oocytes.Device
AI evaluation of oocytes inside a time-lapse incubator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the curve (AUC) will be quantified using logistic regression to assess CHLOE OQ's prediction of blastulation.Time frame: 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The World Egg and Sperm Bank
Scottsdale, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.